BOLD Leadership in Cardiovascular Health

;

Introducing Our Leadership Team

At Amarin, our core values guide every conversation. Our organizational decisions anchor the actions of our employees. Our purpose is motivated by our vision to reduce the burden of cardiovascular disease around the world. Meet our BOLD executive leadership team and our most senior leadership who drive our BOLD vision with courage and care.

Global Management

Board of Directors

President & CEO
Aaron Berg

Mr. Berg joined Amarin in November 2012 and has over 25 years of life science industry experience. Mr. Berg was initially positioned at Amarin as Vice President, Marketing and Managed Care. He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018. He briefly served as the Interim President and CEO in April of 2023 before returning to his position of EVP, President US in July, 2023.

Senior Vice President, Chief Financial Officer
Peter Fishman

Mr. Fishman joined Amarin in January 2019 and has nearly 20 years of experience in various finance areas and leading global finance teams. Mr. Fishman most recently served as the Company’s principal financial and accounting officer since October 2024, and as Vice President & Global Controller since October 2022. Previously, he held roles of increasing responsibility within Amarin’s Finance team since 2019. Mr. Fishman has been involved in numerous complex transactions while with the Company as well as played an integral part in the Company’s current cash management strategy.

Executive Vice President, Technical Operations and President Europe
David Keenan, PHD

Dr. Keenan joined Amarin in May 2022 as Senior Vice President, Technical Operations and is now responsible for the company’s technical operations,supply chain and operations in Europe. David has spent more than 30 years in the biopharmaceutical and medical device industry, with significant experience managing multiple international locations and teams and manufacturing bulk API, sterile drug product and medical devices.

Executive Vice President, President R&D, Chief Scientific Officer
Steven Ketchum, PHD

Dr. Ketchum joined Amarin in February 2012 as President of Research and Development. He brings over 20 years of experience in late-stage product development and clinical regulatory strategy, having led the filings of multiple successful new drug applications (NDAs) and supplemental NDAs.

Executive Vice President, Chief Legal & Compliance Officer
Jonathan Provoost

Mr. Provoost joined Amarin in November 2023 and has more than 20 years of experience in corporate counsel and compliance with medium and large-sized pharmaceutical companies. Mr. Provoost most recently served as Vice President, General Counsel and Chief Compliance Officer at Tris Pharma. Earlier in his career, Mr. Provoost served in roles of increasing responsibility at Mallinckrodt Pharmaceuticals, Ikaria, Kos Pharmaceuticals and Bristol-Myers Squibb.

Company Profile

Amarin focuses on a BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide.

Partnering

Amarin partners with organizations globally to bring innovation and quality to our patients around the world.

Investor Relations

A BOLD investment in cardiometabolic health

Keeping our investors informed about our progress in helping stop cardiovascular disease from being a leading cause of death is important to us. Click here for our investor presentations, events and financial results.

Science and Health

Passionate about cardiometabolic science and health

Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.

Working at Amarin

A BOLD place for entrepreneurial careers

Are you interested in joining Amarin and being part of our BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide? Click here for more information about our culture, career opportunities, benefits and more.

ALL-NP-00015 1/23